1 |
TIAN M J, XU X K, ZHAO S Y. Advance in the treatment of ph chromosome positive acute lymphoblastic leukemia—review[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27(4): 1325-1329.
|
2 |
UCHIDA T, DOKI N, KISHIDA Y, et al. Tyrosine kinase inhibitor maintenance therapy following allogenic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Rinsho Ketsueki, 2020, 61(1): 11-19.
|
3 |
BRISSOT E, LABOPIN M, BECKERS M M, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia[J]. Haematologica, 2015, 100(3): 392-399.
|
4 |
SHORT N J, KANTARJIAN H, PUI C H, et al. SOHO state of the art update and next questions: Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(7): 439-446.
|
5 |
PFEIFER H, CAZZANIGA G, VELDEN V H J VAN DER, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1[J]. Leukemia, 2019, 33(8): 1910-1922.
|
6 |
CHANG J, DAN D E, ALDOSS I, et al. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia[J]. Cancer Med, 2019, 8(6): 2832-2839.
|
7 |
冯术青, 刘志彬, 姚艳红, 等.慢性粒细胞白血病异基因造血干细胞移植术后分层干预治疗疗效观察[J].临床血液学杂志, 2018, 31(1): 44-48.
|
8 |
郑凤美, 孔 军, 赵 婷, 等. 亲缘单倍型与同胞全相合异基因造血干细胞移植后白血病髓外复发的临床特点及预后比较[J]. 中华转移性肿瘤杂志, 2018, 1(3): 30-38.
|
9 |
SAINI L, BRANDWEIN J. New treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Curr Hematol Malig Rep, 2017, 12(2): 136-142.
|
10 |
FIELDING A K, ROWE J M, RICHARDS S M,et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993[J]. Blood, 2009, 113(19): 4489-4496.
|
11 |
SHORT N J, KANTARJIAN H, JABBOUR E, et al. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? [J]. Best Pract Res Clin Haematol, 2017, 30(3): 193-200.
|
12 |
YANG F, CAI W Z, HUANG X W, et al. Comparison of efficacy of first-line administration of generic dasatinib or imatinib in patients with Philadelphia chromosome positive acute lymphoblastic leukemia treated by hematopoietic stem cell transplantation[J]. Zhonghua Xueyexue Zazhi, 2018, 39(8): 661-667.
|
13 |
GIEBEL S, BOUMENDIL A, LABOPIN M,et al .Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for Ph+ALL,A systematic review[J]. Biol Blood Marrow Transplant,2020,26(3):55-64.
|
14 |
TANGUY-SCHMIDT A, ROUSSELOT P, CHALANDON Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study[J]. Biol Blood Marrow Transplant, 2013, 19(1): 150-155.
|
15 |
SLAYTON W B, SCHULTZ K R, KAIRALLA J A, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children’s oncology group trial AALL0622[J]. J Clin Oncol, 2018, 36(22): 2306-2314.
|
16 |
CHALANDON Y, THOMAS X, HAYETTE S,et al .Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia[J].Blood,2015,25(24):3711-3719.
|
17 |
吕梦楠, 张桂新, 张荣莉, 等. 自体与同胞全相合造血干细胞移植治疗ph+急性淋巴细胞白血病的疗效比较[J]. 中华血液学杂志, 2020, 41(5): 373-378.
|
18 |
王建祥.中国复发难治急性淋巴细胞白血病的治疗概况[J]. 中国实用内科杂志, 2021,41(4): 283-290.
|
19 |
王晴晴, 千晨静, 杨菲燕, 等. 移植前微小残留病检测在急性T淋巴细胞白血病患者异基因造血干细胞移植治疗中的意义[J]. 临床血液学杂志, 2021, 34(7): 468-471, 476.
|
20 |
HRABOVSKY S, FOLBER F, HORACEK J M, et al. Comparison of real-time quantitative polymerase chain reaction and eight-color flow cytometry in assessment of minimal residual disease in adult acute lymphoblastic leukemia[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(11): 743-748.
|
21 |
SHORT N J, JABBOUR E, ALBITAR M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts[J]. Am J Hematol, 2019, 94(2): 257-265.
|
22 |
JIANG Q, ZHAO X Y, QIN Y Z, et al. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia[J]. Am J Hematol, 2012, 87(12): 1065-1069.
|
23 |
GREINER G, RATZINGER F, GURBISZ M, et al. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an international scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia[J]. Clin Chem Lab Med, 2020, 58(8): 1214-1222.
|
24 |
李俊南,朱 艳,詹 茜,等.BCR/ABL伴JAK2突变阳性骨髓增殖性肿瘤1例并文献复习[J]. 解放军医学杂志, 2020,45(7): 757-760.
|
25 |
ROSS D M, MASSZI T, GÓMEZ CASARES M T, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study[J]. J Cancer Res Clin Oncol, 2018, 144(5): 945-954.
|
26 |
ZHAO X Y, ZHAO X S, CHEN H, et al. Comparative analysis of flow cytometry and RQ-PCR for the detection of minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(9): 1936-1943.
|
27 |
NISHIWAKI S, IMAI K, MIZUTA S, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT[J]. Bone Marrow Transplant, 2016, 51(1): 43-50.
|